Reporting fourth-quarter financial results late on Thursday, US biotech major Amgen (Nasdaq: AMGN) pleased investors, with its shares rising as much as 3.7% $165.55 in after-hours trading.
The company reported non- generally accepted accounting principles (GAAP) earnings per share of $2.89, a year on year rise of 11% in earnings per share (EPS) versus consensus estimates of $2.79. Non-GAAP operating income increased 2%1 in the fourth quarter to $2.9 billion. Total revenue for the quarter rose 8%coming in at $5.97 billion in revenue, versus consensus estimates and $5.54 billion.
For the full year, total revenues increased 6 to $23.0 billion, with 5 product sales growth. Non-GAAP EPS increased 12% to $11.65, driven by higher revenues and higher operating margins. Non-GAAP operating income increased 14% for the full year to $11.4 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze